The MVA-BN smallpox and monkeypox vaccine, sold as Imvanex in Europe and Jynneos in the United States, has now been widely rolled out in several countries, but questions remain about its effectiveness in real-world use.
A recent US analysis suggests that men who received the vaccine were about 14 times less likely to develop monkeypox, but experts say more research is needed before relying on vaccination alone to curb the monkeypox outbreak.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
NDTV: Mpox can infect and replicate in the brain, NIH researchers say in fatal HIV case
-
[Press release] University of Barcelona: People with HIV did not show more severe clinical symptoms during the 2022 mpox outbreak in Spain
-
[CROI 2026] Healio: Tecovirimat lacks potency against mpox, more studies show
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.